Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 380 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Standard Care Control Clear all
Recruiting Not applicable Interventional

Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers

NCT06681428
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Chronic Foot Ulcers
Interventions
Allograft
Other
Lead sponsor
Tides Medical
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Fresno, California • Los Angeles, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

NCT03215758
View directory record Official record
Conditions
Asthma
Interventions
QAW039, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
42
States / cities
Flagstaff, Arizona • Phoenix, Arizona • Huntington Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jul 23, 2026, 2:12 PM EDT
Recruiting Not applicable Interventional

Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC

NCT06811909
View directory record Official record
Conditions
Non-infected Venous Leg Ulcer, Venous Leg Ulcer, Venous Insufficiency, Venous Stasis, Venous Reflux
Interventions
BR-AC, Standard Care
Other
Lead sponsor
BioStem Technologies
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
23
States / cities
Guntersville, Alabama • Castro Valley, California • Glendale, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 23, 2026, 2:12 PM EDT
Terminated Phase 3 Interventional Results available

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

NCT02312206
View directory record Official record
Conditions
Primary Systemic (AL) Amyloidosis
Interventions
NEOD001, Placebo
Drug · Other
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
32
States / cities
Scottsdale, Arizona • Duarte, California • Stanford, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Jul 23, 2026, 2:12 PM EDT
Withdrawn Phase 3 Interventional

Bone Healing Accelerant Versus Standard of Care for Open Tibia Fractures

NCT03826784
View directory record Official record
Conditions
Tibial Fractures
Interventions
BHA
Combination Product
Lead sponsor
Carmell Therapeutics Corporation
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Jul 23, 2026, 2:12 PM EDT
Terminated Phase 3 Interventional Results available

Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

NCT05179057
View directory record Official record
Conditions
Adenovirus Infection
Interventions
Posoleucel, Placebo
Drug
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
23
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Jul 23, 2026, 2:12 PM EDT
Terminated Phase 3 Interventional

A Study With Imlifidase in Anti-GBM Disease

NCT05679401
View directory record Official record
Conditions
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions
Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids
Drug · Procedure
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 23, 2026, 2:12 PM EDT
Withdrawn Not applicable Interventional

Embecta AID System in Adults With Type 2 Diabetes

NCT06692153
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Type 2 DM, T2DM With Inadequate Glycemic Control, T2DM (Type 2 Diabetes Mellitus), T2D, T2DM
Interventions
An AID System., Standard of Care (SC)
Device · Other
Lead sponsor
Embecta Corp.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Palo Alto, California • Walnut Creek, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Jul 23, 2026, 2:12 PM EDT
Terminated Not applicable Interventional

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window (ImpACT-24A)

NCT03767192
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Active Stimulation, Sham Stimulation
Device
Lead sponsor
BrainsGate
Industry
Eligibility
18 Years to 85 Years
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2019 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics

NCT03162250
View directory record Official record
Conditions
Bacteremia
Interventions
DSTA4637S, Placebo, SOC
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Torrance, California • Detroit, Michigan • Royal Oak, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Jul 23, 2026, 2:12 PM EDT
Terminated Phase 3 Interventional

Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage

NCT02790632
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
EG-1962 (nimodipine microparticles), Enteral Nimodipine
Drug
Lead sponsor
Edge Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Not applicable Interventional

Procellera® Compared to Standard of Care Treatment in Mitigating Biofilm Formation in Acute Trauma and Burn Wounds

NCT04079998
View directory record Official record
Conditions
Trauma-related Wound, Burn, Partial Thickness
Interventions
Procellera®, Standard of Care
Device · Other
Lead sponsor
The Metis Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Jul 23, 2026, 2:12 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Regeneten Patch vs Standard Care in Partial Thickness Rotator Cuff Repair

NCT04673344
View directory record Official record
Conditions
Rotator Cuff Tears, Shoulder Surgery
Interventions
Regeneten Collagen Patch
Device
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
40 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

NCT03737812
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
elezanumab, placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • Berkeley, California • Carlsbad, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Jul 23, 2026, 2:12 PM EDT
Not listed Phase 4 Interventional

A Comparative Efficacy Study of DermaPure™ to Treat Diabetic Foot Ulcers

NCT02081352
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
DermaPure™, Standard care
Other
Lead sponsor
TRx Wound Care Limited
Industry
Eligibility
19 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
7
States / cities
Phoenix, Arizona • Miami, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

NCT03039192
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Placebo, Standard of Care
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Chandler, Arizona • Garden Grove, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout

NCT06186219
View directory record Official record
Conditions
Tophaceous Gout
Interventions
Rituximab
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jul 23, 2026, 2:12 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

NCT01206101
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Jul 23, 2026, 2:12 PM EDT
Active, not recruiting Phase 3 Interventional

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

NCT05126277
View directory record Official record
Conditions
Lupus Nephritis
Interventions
ianalumab s.c. q4w, ianalumab s.c. q12w, placebo s.c.
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
27
States / cities
Birmingham, Alabama • La Palma, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 2 Interventional

NBP in Adult Patients With Acute Ischemic Stroke (AIS)

NCT02905565
View directory record Official record
Conditions
AIS
Interventions
NBP Softgel Capsules, Placebo
Drug
Lead sponsor
CSPC-NBP Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
21
States / cities
Los Angeles, California • Jacksonville, Florida • Des Moines, Iowa + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Jul 23, 2026, 2:12 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

NCT04973137
View directory record Official record
Conditions
Light Chain (AL) Amyloidosis
Interventions
Birtamimab, Placebo, Standard of Care Chemotherapy
Drug · Other
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
22
States / cities
North Haven, Connecticut • Trumbull, Connecticut • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

Combining Lesinurad With Allopurinol in Inadequate Responders

NCT01510158
View directory record Official record
Conditions
Gout
Interventions
Lesinurad, Placebo, Allopurinol
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
165
States / cities
Athens, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 139 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Jul 23, 2026, 2:12 PM EDT
Suspended Phase 2 Interventional

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

NCT05494697
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Rintatolimod
Drug
Lead sponsor
AIM ImmunoTech Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Omaha, Nebraska • Canton, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioactive Split Thickness Skin Allograft Versus Standard of Care in the Treatment of Diabetic Foot Ulcers

NCT04040426
View directory record Official record
Conditions
Diabetic Foot, Ulcer Foot
Interventions
Human split thickness skin allograft, Additional Outer Dressing Applicaiton, Offloading, Fibracol Wound Dressing
Other
Lead sponsor
Professional Education and Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
5
States / cities
San Francisco, California • O'Fallon, Illinois • Youngstown, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Jul 23, 2026, 2:12 PM EDT